Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed a pharmaceutical contract manufacturing agreement worth approximately KRW 1.11T with a pharmaceutical company based in Europe.
📊 [Key Disclosure Details & Financial Figures]
- Contract Title: Pharmaceutical Contract Manufacturing Agreement
- Contract Amount: KRW 1,110,278,292,000 (KRW 1.11T / USD 751,610,000)
- Applied Exchange Rate: USD/KRW 1,477.20 (Initial base rate on December 19, 2025)
- Recent Annual Revenue: KRW 4,547,322,176,421 (Based on 2024 consolidated financial statements)
- Contract Amount to Revenue Ratio: 24.42%
- Counterparty: Pharmaceutical company based in Europe (Counterparty name undisclosed due to business confidentiality)
- Contract Period: December 19, 2025 – December 31, 2030
- Contract Date: December 19, 2025
- Disclosure Postponement Period: December 31, 2030 (Scheduled date for counterparty disclosure)
- Other Important Matters:
- The contract end date is subject to change upon mutual agreement.
- Counterparty identity is slated for disclosure on December 31, 2030, due to business confidentiality, subject to future changes.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Revenue Recognition for Large-Scale Manufacturing Agreement
This disclosure represents a major contract manufacturing deal worth approximately KRW 1.11T, accounting for 24.42% of recent annual revenue.
Monitoring how revenues and earnings from this contract are recognized over the contract period (December 19, 2025 – December 31, 2030) is crucial for understanding the company’s long-term financial performance.
Relevant progress and updates can be verified in upcoming periodic reports and relevant follow-up disclosures.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
